Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Updated late-stage data continue to demonstrate treatment benefit of Novartis' Kisqali in breast cancer

Published 06/02/2017, 07:31 AM
© Reuters.  Updated late-stage data continue to demonstrate treatment benefit of Novartis' Kisqali in breast cancer
NVS
-
  • Updated results from the Phase 3 MONALESSA-2 study continue to show the treatment effect of Novartis' (NYSE:NVS) KISQALI (ribociclib) plus letrozole (FEMARA) in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2-) advanced/metastatic breast cancer. The data will be presented on Sunday, June 4 at ASCO (Abstract #1038).
  • After an additional 11 months of follow-up, median progression-free survival (PFS) in patients receiving the combination was 25.3 months compared to 16.0 months for those receiving letrozole alone (p<0.0001).
  • After two years of treatment, PFS in the combo arm was 54.7% versus 35.9% for the letrozole arm. Median PFS was 27.6 months versus 15.0 months.
  • The FDA approved KISQALI in March for the first-line treatment of HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor.
  • #ASCO
  • Now read: Novartis AG (NVS) Investor Presentation - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.